Analysts forecast that Becton Dickinson and Co (NYSE:BDX) will report sales of $4.12 billion for the current quarter, according to Zacks. Nine analysts have provided estimates for Becton Dickinson and’s earnings, with estimates ranging from $4.07 billion to $4.17 billion. Becton Dickinson and posted sales of $2.97 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 38.7%. The business is scheduled to issue its next earnings results before the market opens on Thursday, May 3rd.
According to Zacks, analysts expect that Becton Dickinson and will report full-year sales of $15.83 billion for the current fiscal year, with estimates ranging from $15.75 billion to $15.90 billion. For the next financial year, analysts expect that the business will report sales of $17.71 billion per share, with estimates ranging from $17.65 billion to $17.83 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Becton Dickinson and.
Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.33 EPS.
In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of Becton Dickinson and stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the transaction, the director now directly owns 295,753 shares of the company’s stock, valued at $64,420,918.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Timothy M. Ring sold 176 shares of Becton Dickinson and stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $218.27, for a total transaction of $38,415.52. Following the completion of the transaction, the director now directly owns 170,688 shares of the company’s stock, valued at $37,256,069.76. The disclosure for this sale can be found here. Insiders sold 281,108 shares of company stock valued at $61,321,396 over the last ninety days. Corporate insiders own 1.00% of the company’s stock.
A number of institutional investors have recently modified their holdings of BDX. Buckingham Capital Management Inc. raised its holdings in Becton Dickinson and by 6.8% in the third quarter. Buckingham Capital Management Inc. now owns 13,895 shares of the medical instruments supplier’s stock worth $2,723,000 after buying an additional 883 shares during the last quarter. Engineers Gate Manager LP purchased a new position in shares of Becton Dickinson and during the third quarter valued at approximately $1,090,000. Segall Bryant & Hamill LLC raised its holdings in shares of Becton Dickinson and by 7.4% during the third quarter. Segall Bryant & Hamill LLC now owns 5,292 shares of the medical instruments supplier’s stock valued at $1,037,000 after purchasing an additional 365 shares during the last quarter. Vident Investment Advisory LLC purchased a new position in shares of Becton Dickinson and during the third quarter valued at approximately $650,000. Finally, Madison Investment Holdings Inc. raised its holdings in shares of Becton Dickinson and by 1.7% during the third quarter. Madison Investment Holdings Inc. now owns 29,931 shares of the medical instruments supplier’s stock valued at $5,865,000 after purchasing an additional 506 shares during the last quarter. 83.46% of the stock is owned by institutional investors and hedge funds.
Shares of BDX traded up $4.20 during trading hours on Wednesday, reaching $229.57. 1,176,843 shares of the company traded hands, compared to its average volume of 1,400,027. The firm has a market capitalization of $60,003.07, a price-to-earnings ratio of 24.22, a PEG ratio of 1.64 and a beta of 1.15. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04. Becton Dickinson and has a 12 month low of $175.66 and a 12 month high of $248.39.
The company also recently announced a quarterly dividend, which was paid on Friday, March 30th. Shareholders of record on Friday, March 9th were issued a $0.75 dividend. The ex-dividend date was Thursday, March 8th. This represents a $3.00 annualized dividend and a yield of 1.31%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 31.65%.
TRADEMARK VIOLATION WARNING: This article was originally published by Week Herald and is the property of of Week Herald. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://weekherald.com/2018/04/23/analysts-expect-becton-dickinson-and-co-bdx-will-announce-quarterly-sales-of-4-12-billion.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.